Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.96 USD | +14.72% |
|
+22.62% | +22.12% |
Jul. 12 | Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating | MT |
Jul. 11 | KalVista Pharmaceuticals Files $300 Million Mixed Shelf | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.12% | 639M | |
+7.40% | 101B | |
+7.76% | 42.18B | |
-14.37% | 32.26B | |
+80.61% | 29.79B | |
-12.27% | 16.06B | |
+2.33% | 14.45B | |
-8.56% | 12.01B | |
+182.74% | 10.71B | |
+4.34% | 8.89B |
- Stock Market
- Equities
- KALV Stock
- News KalVista Pharmaceuticals, Inc.
- KalVista Starts Hereditary Angioedema Trial in Pediatric Patients